MX354283B - Combinacion sinergica para el tratamiento de diabetes mellitus tipo 2. - Google Patents

Combinacion sinergica para el tratamiento de diabetes mellitus tipo 2.

Info

Publication number
MX354283B
MX354283B MX2013014276A MX2013014276A MX354283B MX 354283 B MX354283 B MX 354283B MX 2013014276 A MX2013014276 A MX 2013014276A MX 2013014276 A MX2013014276 A MX 2013014276A MX 354283 B MX354283 B MX 354283B
Authority
MX
Mexico
Prior art keywords
treatment
type
diabetes mellitus
synergistic combination
combination
Prior art date
Application number
MX2013014276A
Other languages
English (en)
Other versions
MX2013014276A (es
Inventor
Farouk Radwan
Original Assignee
Pri S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pri S A filed Critical Pri S A
Publication of MX2013014276A publication Critical patent/MX2013014276A/es
Publication of MX354283B publication Critical patent/MX354283B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La invención se refiere a una combinación sinérgica de cromo trivalente, biotina y ginseng americano eficaz para el tratamiento de diabetes mellitus tipo 2. También se refiere a composiciones dietéticas que incluyen dicha combinación que resultan apropiadas para el tratamiento de diabetes mellitus tipo 2 en pacientes obesos. También se refiere a la utilización de dicha combinación para la preparación de un medicamento para el tratamiento de dicha diabetes.
MX2013014276A 2011-06-08 2012-06-05 Combinacion sinergica para el tratamiento de diabetes mellitus tipo 2. MX354283B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201130956A ES2395529B1 (es) 2011-06-08 2011-06-08 Combinación sinérgica para el tratamiento de la diabetes mellitus tipo 2.
PCT/IB2012/052815 WO2012168854A1 (en) 2011-06-08 2012-06-05 Synergistic combination for the treatment of type 2 diabetes mellitus

Publications (2)

Publication Number Publication Date
MX2013014276A MX2013014276A (es) 2014-05-28
MX354283B true MX354283B (es) 2018-02-21

Family

ID=46513800

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014276A MX354283B (es) 2011-06-08 2012-06-05 Combinacion sinergica para el tratamiento de diabetes mellitus tipo 2.

Country Status (9)

Country Link
US (1) US20140106006A1 (es)
EP (1) EP2717872B1 (es)
AR (1) AR086862A1 (es)
BR (1) BR112013031487B1 (es)
ES (2) ES2395529B1 (es)
MX (1) MX354283B (es)
PT (1) PT2717872T (es)
UY (1) UY34120A (es)
WO (1) WO2012168854A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2489235A (en) 1947-07-24 1949-11-22 Hoffmann La Roche Synthesis of biotin
AU751431B2 (en) 1997-08-08 2002-08-15 Nutrition 21 Chromium/biotin treatment of type II diabetes
IT1311495B1 (it) 1999-06-09 2002-03-13 Mendes S U R L Composizione comprendente sfingomielinasi alcalina, utilizzabile qualeprodotto dietetico, integratore alimentare o medicamento.
WO2002009693A1 (en) * 2000-08-02 2002-02-07 Pharmanutrients Method and compositions for prevention and/or treatment of diabetes and glucose modulation
US6365176B1 (en) 2000-08-08 2002-04-02 Functional Foods, Inc. Nutritional supplement for patients with type 2 diabetes mellitus for lipodystrophy
DE60214849T2 (de) * 2001-02-27 2007-04-26 Nutrition 21, Inc. Chromium/biotin behandlung von dyslipidämie
CN1273152C (zh) 2001-05-11 2006-09-06 上海展望集团有限公司 一种治疗糖尿病的胶囊及其生产方法
AU2006235123A1 (en) 2005-04-07 2006-10-19 Astrum Therapeutics Pty. Ltd. Complementary compositions to reduce blood glucose levels and treat diabetes
EP1996176B1 (en) 2006-02-21 2010-05-19 Astrum Therapeutics Pty, Ltd. Compositions to reduce blood glucose levels and treat diabetes
US20080102137A1 (en) * 2006-10-31 2008-05-01 Guffey Manning V R Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization
CN101390902A (zh) * 2008-10-10 2009-03-25 北京冠五洲生物科学研究院 用于优生优育预防出生缺陷与改善记忆的药物组合物

Also Published As

Publication number Publication date
ES2579829T3 (es) 2016-08-17
EP2717872B1 (en) 2016-04-06
WO2012168854A1 (en) 2012-12-13
ES2395529A1 (es) 2013-02-13
UY34120A (es) 2013-01-03
EP2717872A1 (en) 2014-04-16
BR112013031487B1 (pt) 2020-03-03
ES2395529B1 (es) 2014-04-11
US20140106006A1 (en) 2014-04-17
MX2013014276A (es) 2014-05-28
PT2717872T (pt) 2016-07-11
BR112013031487A2 (pt) 2016-12-13
AR086862A1 (es) 2014-01-29

Similar Documents

Publication Publication Date Title
NZ610034A (en) Prevention of adverse effects caused by cd3 specific binding domains
MX344925B (es) Composiciones de insulina y cromo para el tratamiento y prevención de diabetes, hipoglucemia y alteraciones relacionadas.
PH12015501291B1 (en) Functionalized exendin-4 derivatives
IN2014KN02830A (es)
WO2013158928A3 (en) Chemosensory receptor ligand-based therapies
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MY160894A (en) Oligosaccharide composition for treating skin diseases
MX343687B (es) Compuestos sulfonamida tricíclica y métodos para su fabricación y uso.
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
WO2012054526A3 (en) Chemosensory receptor ligand-based therapies
MX343688B (es) Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
MX2013004699A (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos.
IN2012DN00624A (es)
MX2012006734A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas.
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
AU2018256619A1 (en) Compounds for the treatment of obesity and methods of use thereof
MY150931A (en) Substituted oxazolidinones and their use
WO2012054527A3 (en) Chemosensory receptor ligand-based therapies
WO2012054528A3 (en) Chemosensory receptor ligand-based therapies
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
WO2012054530A3 (en) Chemosensory receptor ligand-based therapies
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
MX2015005111A (es) Composicion a base de hierbas para la prevencion y tratamieto de tnf-a una enfermedad mediada.
HUP0800498A2 (en) Use of dihydralazine for the preparation of medicaments for treatment of diseases related to ssao level

Legal Events

Date Code Title Description
FG Grant or registration